Sign In
Buy TMDX
$76.51
+0.380 (+0.499%)
At Close: Jul 31, 2026
TransMedics (TMDX) Q2 Earnings and Revenues Surpass Estimates
07:06pm, Wednesday, 30'th Jul 2025
TransMedics (TMDX) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.35 per share a year ago.
TransMedics Sees Its Earnings Soar
05:06pm, Wednesday, 30'th Jul 2025
Here's our initial take on TransMedics' (TMDX 2.92%) second-quarter financial report.
TransMedics Reports Second Quarter 2025 Financial Results
04:05pm, Wednesday, 30'th Jul 2025
ANDOVER, Mass. , July 30, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-
Live Earnings: Will TransMedics (TMDX) Rally After Earnings?
12:20pm, Wednesday, 30'th Jul 2025
TransMedics Group reports its Q2 earnings after the bell. Wall Street current expectations stand at: Revenue: $147.74 million Adjusted EPS: $.43 We'll be updating this live blog with updates during th
TransMedics to Present at the Canaccord Genuity 45th Annual Growth Conference
04:05pm, Tuesday, 29'th Jul 2025
ANDOVER, Mass. , July 29, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-
Countdown to TransMedics (TMDX) Q2 Earnings: Wall Street Forecasts for Key Metrics
01:06am, Tuesday, 29'th Jul 2025
Beyond analysts' top-and-bottom-line estimates for TransMedics (TMDX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quar
Why TransMedics Remains A Buy Into 2026
11:57am, Friday, 25'th Jul 2025
TransMedics beat Q1 2025 estimates and raised full-year guidance, showing strong revenue and earnings growth. The company holds a unique market position with the only FDA-approved system for heart, lu
TransMedics to Report Second Quarter 2025 Financial Results on July 30, 2025
04:05pm, Wednesday, 16'th Jul 2025
ANDOVER, Mass. , July 16, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-
TransMedics: Q2 Analyst Estimates Will Fall Short
12:27am, Monday, 14'th Jul 2025
TransMedics has rebounded from a sharp sell-off by consistently beating guidance and demonstrating strong execution, restoring investor confidence. I anticipate Q2 2025 will deliver another earnings b
Is TransMedics Stock a Buy After Short-Seller Drama?
07:00pm, Thursday, 03'rd Jul 2025
Explore the exciting world of TransMedics (TMDX 0.97%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and poten
2 Stocks That Have Doubled This Year and Are Still Worth Buying
04:21am, Monday, 30'th Jun 2025
Positive, company-specific developments have led to shares of TransMedics Group (TMDX 1.08%) and FuboTV (FUBO 2.32%) more than doubling this year, even as the S&P 500 is barely in the green since Janu
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
09:10am, Saturday, 28'th Jun 2025
There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
09:26am, Thursday, 26'th Jun 2025
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
TransMedics' Turnaround: The Organ Transplant Leader Is Still A Buy
10:00am, Monday, 23'rd Jun 2025
TransMedics' Q1 results showcased explosive 48% revenue growth and margin recovery, reaffirming my bullish thesis on its OCS technology and logistics moat. Despite new risks like competition and logis
NEW YORK CITY, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Com
